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Abstract
Recently, many studies have suggested a potential role for early hematopoietic progenitor cell and
hematopoietic stem cell (HSC) recruitment and differentiation in the development of allergy and
inflammation. This is based largely on evidence that stem cells or CD34+ progenitor cells are
recruited to the site of inflammation in allergic diseases, likely through many of the same adhesion
and chemokine receptors used for stem cell homing to the bone marrow (PSGL-1, CXCL12,
alpha4-beta1 integrin, CD44, etc). Once at the site of inflammation, it has been suggested that stem
cells could participate in the perpetuation of inflammation by maturing, locally, into inflammatory
cells in response to the growth factors released in situ. Here we provide a brief review of the
evidence to suggest that hematopoietic stem and progenitor cells (versus mature hematopoietic
lineages) are, indeed, recruited to the site of allergic inflammation. We also discuss the molecules
that likely play a role in this process, and highlight a number of our novel observations on a specific
role for the stem cell antigen CD34 in this process.
Introduction
Recently, many studies have suggested a potential role for
early hematopoietic progenitor cell and hematopoietic
stem cell (HSC) recruitment and differentiation in the
development of allergy and inflammation. This is based
largely on evidence that stem cells or CD34+ progenitor
cells are recruited to the site of inflammation in allergic
diseases, likely through many of the same adhesion and
chemokine receptors used for stem cell homing to the
bone marrow (PSGL-1, CXCL12, α4β1 integrin, CD44,
etc). Once at the site of inflammation, it has been sug-
gested that stem cells could participate in the perpetuation
of inflammation by maturing, locally, into inflammatory
cells in response to the growth factors released in situ. This
is further supported by the recent observation that trans-
plantable HSCs, with the ability to reconstitute all hemat-
opoietic lineages in irradiated hosts, can readily be
isolated from the thoracic duct lymph of mice.
Many of these studies have relied on the use of the CD34
marker to identify HSCs. Antibodies to CD34 have been
extremely useful in stem cell purification for clinical use
and in furthering the understanding of stem cell biology.
Interestingly, through more in-depth analyses, the known
distribution of CD34 in vivo has recently expanded to
include many of the key cell types that participate in aller-
gic inflammation including mast cell and dendritic cell
precursors, and eosinophils [1-4]. Careful analysis of
these cell types derived from CD34-deficient mice has led
to a better understanding of the exact functional role of
CD34 in both stem cell migration and mucosal inflamma-
tory cell homing [4,5]. Here we provide a brief review of
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the evidence to suggest that hematopoietic stem and pro-
genitor cells (versus mature hematopoietic lineages) are,
indeed, recruited to the site of allergic inflammation. We
also discuss the molecules that likely play a role in this
process, and highlight a number of our novel observa-
tions on a specific role for the stem cell antigen CD34 in
this process.
Hematopoietic stem cells and precursors respond to 
inflammatory stimuli both in bone marrow and in 
peripheral tissues
Recruitment of hematopoietic precursors in the lung
There has been a steadily increasing body of literature to
suggest that inflammatory stimuli can have a potent effect
on hematopoietic precursors in the bone marrow as well
as recruitment of these cells to the site of inflammation,
particularly in the lung [6]. Indeed, Denburg and col-
leagues have shown that eosinophil precursors are ele-
vated in the bone marrow during development of upper
and lower airway inflammation, and could contribute to
the continuous production of eosinophils in asthma.
Using a mouse model of upper (allergic rhinitis) and
lower (asthma) airway inflammation, this study showed
that at 24 h post challenge, the number of eosinophil pro-
genitors is increased in the bone marrow after either upper
airway challenge, lower airway challenge, or upper and
lower airway challenges with ovalbumin. This increase
correlated with a boost in mature eosinophils in the blood
and tissue, with a spike in the production of IL-5 and
eotaxin. It was further suggested that this increase in eosi-
nophil progenitors could contribute to the well-described
augmentation in mature eosinophil numbers in blood
and tissue in these models.
Inflammation and recruitment of eosinophils progenitors
In addition to this evidence several additional studies,
conducted in both humans and mice, support the hypoth-
esis that cytokines and chemokines produced during
inflammation influence recruitment and trafficking of
eosinophil progenitors (see figure 1 for a complete list of
molecules and receptors in human and mouse hemat-
opoietic stem cells). For example, it was shown that in
humans, inhaled IL-5 provokes a decrease in CD34+/
CCR3 (eotaxin receptor)+ cells in bone marrow aspirates
and bronchial mucosa, likely due to an increase in recruit-
ment of these cells to the airway lumen [7]. Allergen chal-
lenge has also been shown to provoke an increase in
CD34+/IL5R+ cells in the human airway lumen [8], as
well as an increase in CCR3 expression by CD34+ and
CD34+/IL-5+ populations in bone marrow aspirates [9].
Finally, this CD34+/CCR3+ progenitor population was
shown to migrate in vitro towards the CCR3 ligand,
eotaxin. The idea that cytokines, chemokines or antigen
challenge can provoke the production and migration of
eosinophil progenitors is very interesting indeed, since it
supports the hypothesis that hematopoietic progenitor
production in bone marrow and peripheral migration can
be influenced by an inflammatory environment at distal
sites, and that a constant production of hematopoietic
progenitors promoted by inflammatory mediators could
contribute to the chronicity of inflammatory diseases.
Key hematopoietic stem cell homing receptors are used for 
inflammatory cell migration
Bone marrow homing receptors are also essential in inflammation
With a detailed evaluation of the molecules involved in
hematopoietic cell migration and homing to the bone
marrow, it quickly becomes apparent that these same
receptors are essential for the efficient homing of mature
effector cells to the site of inflammation. For example, the
α4β1 integrin, VLA-4, is a key adhesive receptor for HSCs
in the bone marrow and systemic and administration of
VLA-4 blocking antibodies increases the number of
hematopoietic progenitor cells in circulation[10,11]. Sim-
ilarly, the inflammatory homing selectin ligand, PSGL-1
and its endothelial cell receptors P- and E-selectin, are also
known to play a key role in homing and adhesion of HSCs
to their bone marrow niche [12]. Interestingly, activation
of PSGL-1 by a soluble ligand or an anti-PSGL-1 antibody
leads to suppression of hematopoietic progenitor cell pro-
liferation [13]. The hyaluronic acid (HA) receptor, CD44,
is also known to play a role in both HSC homing and
adhesion to their bone marrow niche [14] and to enhance
the adhesion of inflammatory cells to endothelium at the
sites of inflammation [15,16]. Of further interest, CD44
ligation is also known to stimulate eosinophil precursor
proliferation [17] and could thereby enhance inflamma-
tory cell expansion. Finally, we have shown that CD34,
itself, is expressed by both HSCs and a number of inflam-
matory cell subsets (eosinophils, mast cells, dendritic cell
precursors, etc). Interestingly, on both populations, CD34
appears to act as a type of molecular "Teflon" to enhance
cell mobility and invasiveness and thereby facilitate traf-
ficking of HSCs to the bone marrow and inflammatory
cells to inflamed peripheral tissues [2,4,5]. In summary,
the same repertoire of functional adhesion, homing and
trafficking receptors are expressed by HSCs and inflamma-
tory cells and should endow these cells with a similar
potential for migration.
Inflammatory cytokines and chemo attractants are essential for bone 
marrow trafficking
Intriguingly, just as HSCs and inflammatory cells appear
to use the same slate of adhesion and homing receptors
for migration to the bone marrow and sites of inflamma-
tion, they also rely on the same chemo attractants, growth
factors and cytokines. For example, CXCR4/CXCL12, a
general inflammatory chemokine receptor and chemok-
ine ligand, is the only known chemokine receptor
expressed by HSCs and plays an instrumental role in HSCAllergy, Asthma & Clinical Immunology 2009, 5:13 http://www.aacijournal.com/content/5/1/13
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homing and retention in the bone marrow niche [18,19].
Likewise, c-kit, the receptor for stem cell factor (SCF) and
a known regulator of stem cell growth and proliferation is
also expressed by peripheral tissue mast cells and regu-
lates their chemotaxis, survival, and expansion [20,21].
Moreover, G-CSF (a general inflammatory mediator)
leads to neutrophil precursor activation in the bone mar-
row, MMP release, and proteolytic cleavage of c-kit,
CXCL12 and CXCR4, etc. Cleavage of these molecules
effectively deletes the molecular anchors that attract and
hold HSCs in the bone marrow and leads to their rapid
release into peripheral blood. Further, this blinds HSCs to
Mouse and human expression of shared molecules between inflammation and stem cells Figure 1
Mouse and human expression of shared molecules between inflammation and stem cells. Comparison of mouse 
and human expression of 1) bone marrow homing molecules influencing inflammation, 2) inflammatory molecules influencing 
bone marrow trafficking and 3) inflammatory cytokines produced by hematopoietic stem cells.
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signals that could recruit them back to the bone marrow
until de novo CXCR4 and c-kit membrane receptors can be
expressed on the HSC surface [22,23].
Inflammatory mediators and stem cell recruitment to the site of 
inflammation
In addition to facilitating the potent recruitment of
peripheral blood cells to the site of local inflammation,
there is accumulating evidence to suggest that inflamma-
tory mediators can influence stem cell recruitment and
migration as well. For example, mast cell precursors
respond to CXCL12 and migration of the precursors is
enhanced by the presence of histamine (signalling
through the H4 receptors on mast cell precursors) or
supernatants from IgE-stimulated mast cell cultures [24].
It has also been suggested that the migration of stem cells
to chemotactic ligands is enhanced by the presence of
TNF-alpha [25]. Another study suggests that the CXCR2
ligand GRO-beta mobilizes early stem cells [26]. These
observations, combined with the array of inflammatory
homing receptors expressed on this population suggest
that recruitment of stem cells and hematopoietic progen-
itors may occur in allergy and chronic inflammation. If
they were to differentiate into mature inflammatory cells
in situ, these cells would be well positioned to influence
the chronicity of disease. Since HSC are known to exit and
re-enter the bone marrow through the circulation on a
regular basis [27], they could easily be recruited to the site
of inflammation during their normal homeostatic migra-
tion.
Recently, a study by Massberg et al suggested that HSC are,
indeed, recruited from the bone marrow into the circula-
tion and travel to the liver, peripheral blood, lung, small
intestine and kidney. These authors also detected HSCs in
thoracic duct lymph, which suggests that they have
traveled through the lymph nodes and exited via the effer-
ent lymphatics [28]. In this context, it is intriguing to spec-
ulate on the ability of HSCs to respond to inflammatory
signals by accelerated differentiation into effector cells in
situ. Support for this notion was recently provided by the
observation that HSCs express the innate pathogen pat-
tern recognition receptor, TLR4, and in response to LPS (a
TLR4 ligand), these cells proliferate vigorously in situ, and
differentiate into mature hematopoietic lineages (den-
dritic cells) [29]. This is the first evidence to suggest that
recruitment, proliferation and accelerated maturation of
circulating HSCs in response to an allergen or bacterial
infection could, in fact, have a direct contribution to the
inflammatory immune response.
In summary, during either steady state trafficking, or in
response to potent systemic inflammatory signals, HSCs
are well equipped with the appropriate cytokine receptors,
chemokine receptors and adhesion and homing mole-
cules for trafficking to the sites of inflammation (see fig-
ures 2 and 3). Furthermore, evidence is emerging to
suggest that these cells can respond to inflammatory sig-
nals with the rapid production of required cell types at the
site of inflammation.
Do stem cells, themselves, influence the further 
recruitment of inflammatory cells?
A role for stem cells in chronic inflammation
Several recent studies have argued that the "stem cells",
themselves, could enhance allergy and chronic inflamma-
tion via production of inflammatory factors and chemo-
tactic mediators, thereby promoting recruitment of either
other precursors or mature hematopoietic cells. Following
this line of reasoning, it was shown that human CD34+
progenitor cell supernatants attract RAW 264.7 macro-
phages cells in vitro [30], suggesting that progenitor cell-
produced chemotactic agents are released by hematopoi-
etic precursors. Moreover, in a mouse model of angiogen-
Inflammatory receptors and mediators shared between stem  cells and inflammatory cells Figure 2
Inflammatory receptors and mediators shared 
between stem cells and inflammatory cells. List of 
inflammatory receptors and mediators shared between stem 
cells and inflammatory cells. Modulation of these mediators/
receptors was reported to mediate stem cell mobilising, 
which could allow them to contribute to development of 
inflammatory and allergic diseases. *: receptors that were 
reported to be expressed in stem cells.
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esis, matrigel inserts containing CD34+ progenitor cells
were shown to rapidly recruit monocytes/macrophages as
well as neutrophils in NOD SCID mice in vivo. In this case,
it was shown that attraction of monocytes occurred
through production of IL-8 and MCP-1 by the CD34+ pro-
genitor cells [31]. An additonal recent study has con-
firmed that CD34+ human progenitor can act as effector
cells in allergy. Indeed, it was shown that they express
receptors for the epithelial and mast cells cytokines
thymic stromal lymphopoietin (TSLP) and IL-33 [32].
These two cytokines are known to drive towards Th2- IgE
dependant allergic reactions. Moreover, when these
CD34+ cells were stimulated with the combination of
TSLP and IL-33, they produced a variety of cytokines
including IL-5, IL-13 and GM-CSF. These three mediators
are well known to recruit and promote chronic inflamma-
tion in allergy and asthma. Finally, that study demon-
strated that the sputum from allergic/challenged patients
contained IL-5 and IL-13 positive CD34+ blood cells, con-
firming that an allergic environment leads to cytokine
production by hematopoietic precursors. All in all, this
suggests that CD34+ precursors could participate into pro-
moting chronic inflammation.
Proposed models for the role of stem cells in development of inflammation Figure 3
Proposed models for the role of stem cells in development of inflammation. A) Production of inflammatory media-
tors during inflammation can increase the number of committed progenitor cells. B) Chemotactic mediators released during 
inflammation can provoke the recruitment of stem cells from the circulation to the site of inflammation where they undergo a 
rapid proliferation phase, followed by terminal differentiation into inflammatory cells (mast cells, dendritic cells, eosinophils, 
neutrophils, etc) at the site of the inflammatory reaction, contributing to development and chronicity of disease. C) Inflamma-
tory mediators provoke the release of proteases (MMPs) by granulocytes or stem cells within the bone marrow, which cleave 
the molecular anchors of stem cells and increase their release in the circulation.
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CD34+ cells in mice: a pure population of progenitor cells?
A caveat to this previous model, however, is that CD34
has recently been shown to be expressed on a number of
mouse inflammatory cells and precursors (such as mast
cells, eosinophils and dendritic cells). Thus, it is possible
the inflammatory cytokines detected in this study where
produced by more mature CD34+ inflammatory cells
rather than CD34+ progenitor cells. Our observation that
CD34+ mast cells and their precursors express the same
cohort of cell surface markers and antigens[2] suggest that
great care must be exercised in distinguishing stem cells
from mast cells. Since mast cells are extremely potent elab-
orators of inflammatory mediators and are present in
peripheral tissues at the same frequency as circulating
stem cells, this represents a significant problem in the
interpretation of many previous studies.
Contribution of stem cells to inflammatory disease: a possible clinical 
implication
With the afore mentioned caveat aside, functional assays
have confirmed that bona fide HSCs and hematopoietic
precursors, with the ability to generate multiple hemat-
opoietic lineages in lethally irradiated recipients, do circu-
late through the peripheral blood and lymph and
therefore are positioned to home to the sites of inflamma-
tion. Although it could be argued that the numbers of
these circulating and recruited progenitors would be too
low to make a major contribution to allergy and inflam-
matory disease development, it is important to bear in
mind that as HSCs enter the differentiation pathway and
become "transient amplifying cells", they exhibit a truly
remarkable capacity for proliferation and expansion. This
expansion of precursors prior to terminal differentiation
and would allow a very limited number of recruited stem
cells to have a major impact on local inflammatory cell
generation. There are no studies to date that have investi-
gated whether blockade of their recruitment could influ-
ence the course of inflammation. However, a closer look
at the blockade of some molecules implicated in their traf-
ficking could help us determine whether this avenue
could be of therapeutic value.
Conclusion
The evidence of shared receptor expression and chemotac-
tic potential between inflammatory cells and stem cells is
convincing. Moreover, there seems to be a direct effect of
inflammation on stem cell recruitment, potentially redi-
recting the homing of HSCs destined for the bone mar-
row, to the site of inflammation in diseases like allergy. As
the understanding of these interactions grows, we should
have a better impression of the extent of stem cell recruit-
ment to the development of allergic inflammatory dis-
eases.
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